Arrow ErgoPack and AC3 Optimus Product Overview
UroLift: Reducing Tradeoffs Between Effectiveness and Risk
Compared to Drugs
Time to First Evidence of
Statistically Significant
Relief (Weeks) 1,2,3,4,5
12-24
5ARI
Symptom Improvement
Incidence of Sexual Dysfunction
at 10-16 Months 5,6,7
Mean AUASI Reduction
Ejaculatory Dysfunction
Erectile Dysfunction
1-3
3.4
2
AB
UROLIFT
5.6-
5 7
65
7.5
10.8
4%
0%-
10%
8%
3%-
5%
0%
5ARI
AB
UROLIFT
5ARI
AB
UROLIFT^5,7
5ARI
AB
DRUGS: 5ARI = 5 alpha reductase inhibitors
AB alpha blockers
Symptoms measured by AUASI (American Urological Association Symptom Index)
^ Sexual Dysfunction defined as new, onset sustained erectile or ejaculatory dysfunction.
0%
UROLIFT™^5,7
29
1. Roehrborn, Rev Urol 2009; 11(suppl 1): S1-S8; 2. Rossi, Drug Des, Dev and Therap 2010; 4: 291-297 3. Pearson, Am Fam Phys 2014; 90 (11): 769-774; 4. Cindolo, Eur Urol 2015
Sep; 68(3): 418-25; 5. Roehrborn, J Urol 2013; 190: 2161-2167; 6. Sonksen, Eur Urol 2015; 68: 643-652; 7. AUA Guidelines 2003, 2010, 2014, which address a range of outcomes
across alfuzosin, doxazosin, tamsulosin, and terazosin for ABS and only finasteride for 5ARIS
Teleflex®View entire presentation